Przeglądaj wg Słowo kluczowe "schizophrenia"

Teraz wyświetlane 1 - 4 z 4
  • Miniatura
    Pozycja
    Caregiver burden in relatives of patients with schizophrenia – reality and methods of support
    (Oficyna Wydawnicza AFM, 2020) Fusińska-Korpik, Agnieszka
    Schizophrenia is a chronic disease that affects about 1% of the population. Scientific interest in the families of sick people has been rooted in the search for systemic factors affecting the onset, course and prognosis of the illness. Today, more and more attention is being paid to the role of the family as a source of support in the treatment process, and family cohesion is considered a positive prognostic factor. A person with schizophrenia often needs accompanying in the recovery process, therefore the patient’s relatives can be a source of instrumental and socio-emotional support, oft en providing motivation for treatment and rehabilitation. Still, in the public health system the opportunities to support the patient’s family are relatively small and limited to single initiatives. At the same time, research results and clinical experiences suggest that caregivers often feel overwhelmed by daily duties, feel a lack of reliable knowledge, and it is difficult for them to adjust themselves to their new role. This chapter provides scientific reflection on the consequences of caring for a person with schizophrenia. The state of the study and the possibilities of holistic support for the patient and his family system are analyzed.
  • Miniatura
    Pozycja
    Family - Health - Disease
    (Oficyna Wydawnicza AFM, 2020) Gołkowski, Filip; Kalemba-Drożdż, Małgorzata; Fusińska-Korpik, Agnieszka; Skorupska-Król, Agnieszka; Kurleto, Paulina; Dębska, Grażyna; Pawłowski, Leszek; Bil, Jakub; Bajcarczyk, Renata; Florek, Renata; Kozieł, Dorota; Witkoś, Joanna; Grzywacz-Kisielewska, Agata; Kin-Dąbrowska, Joanna
    Preface: "The family is the basic social cell and a person’s closest environment; it plays the dominant non-medical role in shaping health as it is the primary source of knowledge about nutrition, life-style and disease prevention. The family may determine both healthy habits and anti-health behaviors; it influences the entire duration of a person’s life. It is important to emphasize the extremely significant role of the family in providing care, supporting treatment processes, and giving company to an ill family member."(...)
  • Miniatura
    Pozycja
    Interdyscyplinarne aspekty nauk o zdrowiu
    (Oficyna Wydawnicza AFM, 2010) Goździalska, Anna; Jaśkiewicz, Jerzy; Lizak, Dorota; Kalemba-Drożdż, Małgorzata; Drąg, Jagoda; Gawędzka, Anna; Brzewski, Paweł; Wojas-Pelc, Anna; Limanówka, Danuta; Foryś, Zofia; Pach, Dorota; Targosz, Dorota; Gołkowski, Filip; Dęsoł, Agnieszka; Abramczyk, Anna; Seń, Mariola; Felińczak, Anna; Dębska, Grażyna; Hama, Faustina; Krzyżanowski, Dominik; Słobodzian, Anna; Knapik-Czajka, Małgorzata; Kozak, Lidia; Drożdż, Włodzimierz; Kurleto-Kalitowska, Ewa; Romanowska, Urszula; Lipińska, Maria; Maj, Krystyna; Lampart, Beata; Laskowska, Justyna; Drożdż, Włodzimierz; Kadučáková, Helena; Lehotská, Mária; Czajkowski, Wojciech; Pawłowski, Leszek; Kiwnik-Dahm, Aneta; Cepuch, Grażyna; Futoma, Bernadetta; Pasek, Małgorzata; Jackowska, Renata; Dębska, Grażyna; Jaśkiewicz, Jerzy
  • Miniatura
    Pozycja
    Peripheral complement C3 and C4 are associated with clinical features of schizophrenia
    (Frontiers, 2026-03-30) Szwajca, Marta; Śmierciak, Natalia; Biesaga, Beata; Donicz, Paulina; Szwajca, Krzysztof; Pilecki, Maciej
    Aim: Schizophrenia is a severe psychiatric disorder with heterogeneous outcomes; factors such as anxiety, childhood trauma, and duration of untreated psychosis (DUP) may influence symptom severity and disease progression. Growing evidence highlights immune dysregulation—particularly alterations in complement components C3 and C4—in the pathophysiology of schizophrenia; however, findings regarding peripheral complement levels and their clinical associations remain inconsistent. Method: Thirty-nine patients with schizophrenia underwent clinical assessment using the Childhood Trauma Questionnaire (CTQ), the Positive and Negative Syndrome Scale (PANSS), the State–Trait Anxiety Inventory (STAI), and the Montreal Cognitive Assessment (MoCA). Serum concentrations of C3 and C4 were measured at admission. Results: In exploratory analyses (nominal p-values), baseline C3 correlated with DUP (r=0.407, p=0.010) and length of hospitalization (r=0.353, p=0.028). Higher C3 was associated with greater symptom severity on PANSS-P1 (r=0.325, p=0.043) and PANSS-G1 (r=0.330, p=0.040), while C4 correlated with PANSSG1 (r=0.322, p=0.045) and multiple PANSS domains after 12 weeks. C3 was associated with anxiety at baseline and after 3 months (STAI-T1: r=0.376, p=0.018; STAI-S1: r=0.372, p=0.020; STAI-T2: r=0.376, p=0.018; STAI-S2: r=0.419, p=0.009), whereas C4 correlated with STAI-T1 (r=0.361, p=0.024), STAI-S1 (r=0.342, p=0.033), and STAI-S2 (r=0.338, p=0.038). Higher C3 and C4 levels were associated with CTQ subscales. C3 correlated negatively with cognitive performance (MoCA1: r=–0.339, p=0.034). However, none of the associations survived Benjamini–Hochberg false discovery rate (BH-FDR) correction (all q>0.05). Conclusion: These exploratory, within-cohort findings suggest that peripheral complement markers relate to variation in clinical severity and illness-course indicators in schizophrenia. Replication in larger, controlled longitudinal studies is warranted.